• Home
  • >
  • Alembic Pharmaceuticals Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/alembic-pharmaceuticals-ltd.png Logo

Alembic Pharmaceuticals Ltd Financial Statement

Alembic Pharmaceuticals Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue1,481.771,591.691,487.79
Operating Expense1,186.361,251.251,271.38
Net Profit201.87233.24133.84
Net Profit Margin13.6214.659
Earning Per Share10.2711.876.81
EBIDTA295.41340.44216.41
Effective Tax Rate4.846.89TBA

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Alembic Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual5,652.625,305.795,393.13
Operating Expenses Annual4,944.264,431.633,912.84
Operating Profit Annual680.19929.91,567.58
Interest Annual50.1717.7316.02
Depreciation275.43286.78183.48
Net Profit Annual341.99520.941,146.5
Tax Annual12.6104.45253.32

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Alembic Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning61.0998.0671.84
Cash Flow from Operations723.94552.351,463.39
Cash Flow from Investing-447.59-371.97-839.74
Cash Flow from Financing-261.96-217.35-597.43
Cash Flow at the End75.4861.0998.06

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Alembic Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)12.0317.5329.07
PBIT Margin (%)7.1612.1225.66
PBT Margin (%)711.423.95
Net PROFIT Margin (%)6.7310.7921.64
Return On Networth / Equity (%)7.1210.1126.91
Return On Networth /Employed(%)7.210.9125.51
Return On Assets (%)6.739.7221.64
Total Debt / Equity(X)0.150.120.27
Asset Turnover Ratio (%)10.91

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Alembic Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual2,398.451,896.292,026.67
Total Current Assets Annual2,910.022,860.792,652.02
Non Current Assets Annual3,272.814,261.244,056.96
Total Shareholders Funds Annual4,370.475,237.545,066.97
Total Assets Annual6,182.837,122.036,708.98

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Alembic Pharmaceuticals Ltd Earning Calls
Mar 2024
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Alembic Pharmaceuticals Ltd has a market capitalization of 19,309.38 Cr. Value Research classifies it as a Large-Cap company.

Yes, Alembic Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.11.

In FY 2023, Alembic Pharmaceuticals Ltd recorded a total revenue of approximately 6,228.63 Cr marking a significant milestone in the company's financial performance.

Alembic Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..

Alembic Pharmaceuticals Ltd's current PE ratio is 31.36.

Alembic Pharmaceuticals Ltd's ROCE averaged 10.6% from the FY ending March 2022 to 2024, with a median of 10.8%. It peaked at 12.9% in March 2024, reflecting strong capital efficiency over the period..

Alembic Pharmaceuticals Ltd's latest EBIT is Rs. 688.02 Cr, surpassing the average EBIT of Rs. 578.63 Cr over the 5 years..